Heidelberg Druck's Reinvention Gamble: Can Drones and Batteries Outrun a Bleak Quarter?

Heidelberg posts €32M Q1 loss amid 13% revenue drop, but diversifies into Ukrainian drones and sodium-ion batteries to offset print decline.

The numbers out of Heidelberg Druckmaschinen's first quarter read like a warning. Revenue fell 13 percent to €404 million, adjusted EBITDA collapsed from €20 million to €1 million, and the bottom line swung to a net loss of €32 million. Yet the company's leadership is pointing investors toward a very different story — one built on Ukrainian drone technology and sodium-ion battery storage rather than the printing presses that built the 170-year-old German machinery group.

The diversification push came into sharper focus this week as the company confirmed two parallel initiatives. A partnership with Ukrainian drone developer SKYETON targets the European defense market, while subsidiary HD Advanced Technologies has signed a manufacturing agreement with Switzerland's Phenogy AG for sodium-ion battery storage, with a joint venture for cell production in preparation. For a company whose core business has struggled with declining orders for years, these represent unusually bold bets beyond the print industry.

A Quarter That Tests Patience

The financial backdrop to this strategic pivot is unforgiving. Order intake slipped nearly 4 percent to €537 million, a decline largely attributed to the expiry of a state-subsidized investment program in Italy — an effect that alone cost the company more than €60 million. The net loss of €32 million was nearly three times the €11 million loss recorded in the same period a year earlier.

Management nonetheless reaffirmed its full-year guidance: revenue should hold at roughly the prior year's level of around €2.3 billion, with a noticeable improvement in the adjusted EBITDA margin from the 6.6 percent posted last year. The first quarter's adjusted EBITDA margin of just 0.2 percent illustrates the scale of the challenge — the new ventures in defense and battery technology are, at least in part, an attempt to reduce dependence on a cyclical printing machinery business that is currently generating little in the way of profitability.

The Execution Question

Whether the diversification strategy can deliver before the core business erodes further is the central question hanging over the stock. The battery and drone operations remain in early contractual or preparatory phases — the Phenogy joint venture has been announced but not completed, and the SKYETON cooperation has yet to translate into concrete order volumes.

There are some supportive elements. The integration of manroland sheetfed's lifecycle business and the full takeover of Polar's post-press production are strengthening recurring service revenues, which should help stabilize margins. Warburg Research analyst Stefan Augustin described the quarterly results as a seasonally typical start with solid order intake, maintaining a "Buy" rating with a price target of €1.80.

The bear case is equally straightforward. With a first-quarter net loss of €32 million, the financial cushion for experimenting with new technology fields is thin. If revenue contributions from the new ventures fail to materialize while the core business operates at a 0.2 percent adjusted EBITDA margin, the annual guidance could become a liability rather than an anchor of confidence.

New Finance Chief Enters the Fray

Adding another layer of complexity, the company announced a change at the top of its finance department. Christoph Burkhard will take over as chief financial officer on October 1, 2026, assuming responsibility for finance, controlling, investor relations, M&A, accounting, legal, tax, and information security. His predecessor, Volker Herdin, retires on September 30, 2026.

The transition lands at a delicate moment. Burkhard will inherit the task of allocating capital between a struggling core business and multiple capital-intensive future projects — from integrating acquired operations to building new production lines for battery storage. His appointment will serve as a concrete test of how the company prioritizes these competing demands.

Market Waits for a Signal

The share price reflects the uncertainty. Trading at €1.44, barely above the previous close of €1.43, the stock sits almost exactly on its 50-day average of €1.42. It remains roughly 40 percent below the 52-week high of €2.40 but only 11 percent above the recent low of €1.29 hit on March 13. Over twelve months, the shares have lost 31 percent; since the start of the year, the decline stands at 29 percent.

That proximity to the low suggests the market has already priced in the weak quarterly figures but is waiting for evidence that the new business lines can generate recurring, margin-rich revenue. The moderate volatility of 22 percent points to no acute panic — rather, a patient, watchful stance.

The path forward hinges on whether the partnerships with Phenogy and SKYETON move from preparation to production quickly enough to support the promised margin improvement. Should the joint venture with Phenogy face delays or the SKYETON cooperation fail to produce tangible orders, attention will likely swing back to the thin core margin, potentially pushing the stock toward its 52-week low. For now, the transformation story remains intact — but it is a story built on promises that have yet to be proven in the numbers.